Celadon Pharmaceuticals PLC Notice of Results and Investor Presentation (7393A)
26 Mayo 2023 - 1:00AM
UK Regulatory
TIDMCEL
RNS Number : 7393A
Celadon Pharmaceuticals PLC
26 May 2023
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notice of Results and Investor Presentation
LONDON, 26 May 2023: Celadon Pharmaceuticals Plc (AIM: CEL), a
UK-based pharmaceutical company focused on the research,
cultivation, manufacturing and sale of breakthrough cannabis-based
medicines, will announce its results for the year ended 31 December
2022 on Monday 5 June 2023.
Analyst Briefing: 10.00am, Monday 5 June 2023
Management will host a virtual analyst presentation followed by
a Q&A session at 10.00am BST on Monday 5 June 2023. Analysts
wishing to join should register their interest by contacting
celadon@powerscourt-group.com .
Investor Presentation: 3.30pm, Monday 5 June 2023
Management will be hosting a live presentation and Q&A
session via the online platform, Investor Meet Company, at 3.30pm
BST on Monday 5 June 2023.
The presentation is open to analysts and all existing and
potential shareholders. Questions can be submitted pre-event via
the Investor Meet Company dashboard up until 9.00am on Monday 5
June 2023 or at any time during the live presentation. Investors
can sign up to Investor Meet Company for free via:
https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
Investors who already follow Celadon on the Investor Meet
Company platform will automatically receive an invitation to the
event.
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Bobbie Hilliam / Andrew Potts / Patrick
Dolaghan +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0)20 7250 1446
/ celadon@powerscourt-group.com
Ibrahim Khalil
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and sale of
breakthrough cannabis-based medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and manufacturing and an analytical and R&D
laboratory. Celadon's Home Office licence allows for the commercial
supply of its GMP pharmaceutical cannabis product. The Company's
subsidiary, LVL, owns a MHRA conditionally-approved clinical trial
using cannabis based medicinal products to treat chronic pain in
the UK. Celadon also has a minority interest in early-stage
biopharma Kingdom Therapeutics which is developing a licenced
cannabinoid medicine to treat children with Autism Spectrum
Disorder.
For further information please visit our website
www.celadonpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORNKPBKBBKBAPB
(END) Dow Jones Newswires
May 26, 2023 02:00 ET (06:00 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Celadon Pharmaceuticals (LSE:CEL)
Gráfica de Acción Histórica
De May 2023 a May 2024